Disitamab Vedotin (RC48-ADC) in Breast Cancer

Shanghai Jiao Tong University

Status: Enrolling

Conditions: Breast Cancer

Treatments: Drug: Disitamab vedotin

Study type: Observational

Funder types: Other

Identifiers

NCT05851677

LY2023-062-B

Details and patient eligibility

About

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.

Enrollment: 45 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed breast cancer;
• Prior or current use of Disitamab vedotin (RC48-ADC);

Exclusion criteria

• Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.

Trial design

45 participants in 1 patient group

RC48-ADC

Description:

RC48-ADC for breast cancer

Treatment:

Drug: Disitamab vedotin